Stellantis warns of US$2.7 billion loss for 1st half of 2025 due to tariffs and some big charges
Stellantis, the maker of Jeep and Ram vehicles, says its preliminary estimates show a 2.3 billion euros (US$2.68 billion) net loss in the first half of the year due to U.S. tariffs and some hefty charges.
The automaker anticipates an impact of about 300 million euros for net tariffs incurred, and also expects planned production losses related to implementing its response plan.
Stellantis also expects approximately 3.3 billion euros ($3.84 billion) of pre-tax net charges mostly related to program cancellation costs and platform impairments, restructuring and the net impact of recent legislation eliminating the CAFE penalty rate. Automakers have been penalized if the average fuel economy of a their annual fleet of vehicle production exceeds a certain level.
Two months ago Stellantis named Antonio Filosa as its new chief executive officer. He replaced Carlos Tavares, who resigned under pressure last year.
Stellantis, which was created from the 2021 merger of France's PSA Peugeot with Italian-U.S. carmaker Fiat Chrysler Automobiles, is the world's fourth-largest car manufacturer. It is based in the Netherlands.
The automaker provided preliminary financial figures on Monday in the absence of financial guidance, which it suspended in April.
Michelle Chapman, The Associated Press
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CBC
25 minutes ago
- CBC
Regina couple's app teaches mindfulness to break the cycle of addiction
It began with moments of personal reflection. Adam Geiger had been battling a gambling addiction since he was a teenager. "I think it started innocently enough, with things like video games and whatnot," Geiger said. "Looking back, I remember myself being very anxious, always really trapped in my mind thinking of what other people thought of me." After decades of struggle, mindfulness and meditation helped him shift gears, allowing him to explore not just his behaviour, but the thoughts beneath it. "Looking at the nature of thought and what was going on, sort of beneath the surface level stuff," he said. In 2024, he and his partner Chelsea Galloway two decided to build a digital tool to support others facing similar struggles. "I think Adam and I both had this opportunity at the time to really be able to put ourselves into something that mattered to us personally," Galloway said. A year and a half later, their vision became reality with the launch of AlchemistOne, a mindfulness-focused recovery app designed to support people dealing with addictions. A shared mission born from experience Geiger's journey to AlchemistOne began decades ago, when an innocent love of video games and sports grew to compulsive gambling. "I made my first sports bet when I was 13 or 14," he said. "All those thoughts went away and it was very easy for me to escape into gambling." Temporary relief came with long-term consequences. Geiger said he spent more 20 years locked in a cycle of gambling addiction. Once he finally broke that cycle, the app seemed like a perfect opportunity to help others do the same. Galloway, the company's COO, brought both personal insight and business expertise to the project. "Addiction was just something that was really present in our lives," she said. "Adam had a really strong tech background. I had a pretty strong business background. So we came together to build the company." The pair spent months designing what would become AlchemistOne. What started as a two-person initiative now includes six full-time team members and a growing community of close to 6,000 downloads worldwide. A 3-pillar approach Geiger said that at its core, AlchemistOne is built around three key pillars of recovery: Mindfulness and meditation. Active reflection. Physical movement. Users can access a library of audio content, including guided meditations, podcast-style interviews and personal stories from people around the world who are in recovery. Geiger acknowledged an irony in people using the same phone or tablet that accessed gambling sites, social media or other addictive content as a tool for recovery. Instead of turning to a casino app or a harmful distraction, users can open AlchemistOne and engage in a quick mindfulness session. "I think often our phones and our computers are the things that we use to escape into and keeps us a lot of trouble," he said. "We definitely wanted to build that daily companion that lived in that same space that you maybe had some trouble before." Since the launch in April 2025, the response has been swift and steady the pair says. "It's really exciting that we see new members every five or 10 minutes jumping into the app and signing up," Galloway said. For both founders, the real win isn't downloads, it's impact. "We're getting that feedback from people who are saying, you know, this is resonating with me," Galloway said. "It's complicated, it's complex. And if we can just bring something to the table that helps people get through their day and potentially helps long lasting recovery, that's really the end goal."
Globe and Mail
an hour ago
- Globe and Mail
Meet the 7.3% Yield Dividend Stock That Could Soar in 2026
Key Points Pfizer is doing well enough to pay down debt while sustaining its generous dividend. Oncology and specialty drugs are driving growth. The stock has a high ceiling heading into next year. 10 stocks we like better than Pfizer › It's been a tough stretch for pharmaceutical giant Pfizer (NYSE: PFE). The company enjoyed a vaccine windfall during the COVID-19 pandemic, but revenue and profits cratered as the pandemic eased and those tailwinds stopped blowing. The stock has tumbled, sending Pfizer's dividend yield to a whopping 7.3%. But Pfizer's stock price recently bounced on its second-quarter earnings. Investors have been looking for a glimpse into Pfizer's future, and there is a lot to like as things begin to come into view. Here is why Pfizer's newfound momentum could set the stock up to soar in 2026. Prudent financial management secures a generous dividend Pfizer's generous dividend has become a big reason why many people consider owning the stock. It's not easy to find a 7.3% dividend yield, and oftentimes, stocks that do are yield traps with significant underlying risks. While the market's negative sentiment toward Pfizer and the company's post-pandemic struggles have driven the share price down and the yield higher, the dividend itself is on solid footing. Management has raised the dividend for 15 consecutive years, so losing those pandemic-related profits didn't force a dividend cut. Additionally, the current dividend of $1.72 per share is well below the mid-point of management's 2025 adjusted EPS guidance of $3 per share. In other words, Pfizer is still earning plenty of money to afford its dividend, and is using that cushion to, wisely, pay down debt to improve its balance sheet. That's prudent financial leadership, and should give investors some confidence that they can count on the stock's robust 7.3% yield as a nice baseline for the stock's future returns. Is Wall Street sleeping on Pfizer's growth? It seems the broader market is cautious toward healthcare stocks at the moment. Not only could tariffs raise costs for drug companies, but there is also pressure from the Trump administration to cut prescription drug prices for Americans. However, Pfizer seems to be increasingly confident that it can navigate these headwinds and grow its business. Management recently raised its 2025 adjusted earnings guidance from a range of $2.80 to $3.00 per share to $2.90 to $3.10. The company has focused its growth efforts on oncology and specialty drugs, which are less likely to face pricing pressure. And that's precisely where Pfizer is growing the most; the company's specialty drug sales are up 6% year over year, and oncology sales are up 9% through six months of 2025. As specialty and oncology drug sales increase, they should have a greater effect on Pfizer's overall growth. These two segments combined for approximately $16.5 billion through six months of this year. Pfizer's primary care drug sales, totaling $11.2 billion, are down 8% year over year as COVID-19 sales continue to fall off. Six-month sales of Pfizer's COVID-19 drugs are now less than $2 billion, so their impact on the numbers is drying up. Additionally, Pfizer's top seller, Eliquis, faces patent expiration but likely won't face generic competition until at least 2028. Analysts only anticipate Pfizer earning $3.10 per share next fiscal year, but that could be too conservative, given Pfizer's momentum in oncology and specialty drugs and the resulting boost to this year's guidance. It seems tariff and political concerns are weighing on short-term expectations. If you zoom out, analysts anticipate Pfizer growing earnings at an annualized rate of 9% over the next three to five years, which seems to underline the good things happening in the business. The conditions are ripe for a dramatic sentiment boost, making Pfizer a coiled spring at its current price So, what does this all mean? There's an argument that Pfizer's stock could face a boost in sentiment if the dark clouds (tariffs and political pressure) clear out, allowing investors to refocus on Pfizer's growth in oncology and specialty drugs. Today, Pfizer trades at just 8 times the midpoint of its 2025 earnings guidance. That valuation resembles a company on the verge of going under, not one that could grow at a high-single-digit pace over the coming years. Even if the valuation stays the same, Pfizer needs very little growth to generate double-digit investment returns because the dividend starts you off at over 7%. If things do go well and Wall Street warms up to Pfizer, the stock could produce some seriously outsized returns from a lucrative trifecta of: A 7.3% dividend Potential high-single-digit growth A valuation that could soar with some positive sentiment It makes Pfizer a fantastic choice for income-focused investors, as well as bargain hunters looking for some upside in a market already trading at all-time highs, chugging toward 2026. Should you invest $1,000 in Pfizer right now? Before you buy stock in Pfizer, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Pfizer wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $653,427!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,119,863!* Now, it's worth noting Stock Advisor's total average return is 1,060% — a market-crushing outperformance compared to 182% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 4, 2025
Globe and Mail
an hour ago
- Globe and Mail
This AI Stock Just Hit a 52-Week Low -- Here's Why That's an Opportunity
Key Points Confluent recently hit a 52-week low, as investors were not impressed by management's latest guidance. However, the company is growing at a brisk pace and building a solid revenue pipeline. An increase in AI-focused workloads should pave the way for stronger growth at Confluent, and its valuation makes it worth buying right now. 10 stocks we like better than Confluent › Data streaming platform provider Confluent (NASDAQ: CFLT) saw a sharp drop in its share price this year, which was blamed on slowing growth. Things went from bad to worse following the release of the company's latest quarterly results. Confluent reported its second-quarter results on July 30. The stock shed almost a third of its value the following day and also touched a 52-week low on Aug. 1. Investors were quick to press the panic button despite Confluent's better-than-expected results, as management's guidance didn't inspire much confidence. Savvy investors looking to buy a potential artificial intelligence (AI) winner should consider using Confluent's dip as a buying opportunity. Here's why. AI could give Confluent a nice shot in the arm Confluent reported a 20% year-over-year increase in its revenue in the previous quarter to just over $282 million. Its earnings growth was even more impressive at 50%, to $0.09 per share. Confluent management remarked on the latest earnings conference call that it is navigating a tight spending environment. The company, which operates a cloud-based data streaming platform to store, access, connect, and manage customers' data and applications in real time, says that its growth was hindered by customers' "optimization" initiatives. According to CEO Jay Kreps: In Q2, our larger customers continued their optimization efforts and adopted new use cases in a more measured pace. While we are confident that this elevated level of optimization will eventually subside, our outlook for the second half assumes consumption growth notably below what we've seen in the same period of prior years. Unsurprisingly, investors were spooked by this forecast of slowing sales growth in the second half of the year. But at the same time, one shouldn't forget that Confluent has slightly increased the lower end of its 2025 revenue guidance. What's more, the company's future revenue pipeline is improving at a brisk pace despite the controlled spending by customers. This is evident from the 31% increase in its remaining performance obligations (RPO) in the previous quarter. RPO is the total value of a company's unfulfilled contracts at the end of a period. This metric grew at a much faster pace than the growth in Confluent's top line. That's good news, as the faster growth in Confluent's revenue backlog should allow it to eventually increase its growth rate in the future once it starts fulfilling the contracts that it's signing now. Meanwhile, the company expects a big boost from the adoption of AI services in the cloud. Confluent says that it saw an increase in the number of customers using its data streaming platform to support real-time AI workloads such as agentic AI applications, code generation, content creation, chatbots, and others. In fact, Confluent says that it expects "production AI use cases to grow 10x across a few hundred customers" in 2025. The company cited several examples where customers around the globe are using its data streaming solutions to build AI agents capable of handling real-time queries. Looking ahead, there's a good chance that more customers could flock to Confluent's cloud-based platform, thanks to the sharp increase that it's predicting in real-time AI use cases. This explains why analysts expect an improvement in Confluent's earnings growth rate in the future. Data by YCharts. The valuation makes the stock an attractive buy The sharp drop in Confluent's stock price this year explains why it is trading at an attractive 5 times sales right now, less than half its average five-year sales multiple. Moreover, Confluent stock trades at a discount to the U.S. technology sector's average sales multiple of 8.4. Investors can consider buying Confluent at this discounted multiple, since it is clocking a healthy revenue growth rate despite controlled customer spending. Analysts also expect its top line to grow in the mid-teens for the next couple of years, though don't be surprised to see Confluent doing better than that, given the pace at which its revenue backlog is improving. Data by YCharts. If the company indeed manages to outpace Wall Street's revenue expectations over the next couple of years, the market could reward it with a higher sales multiple. That could pave the way for healthy stock price upside. Even if Confluent's revenue increases to $1.57 billion in 2027 (as per the previous chart) and it trades at even 7 times sales at that time (a discount to the U.S. technology sector's average), its market cap could hit $11 billion. That would be an increase of 86% from current levels. So, investors looking for an AI stock that's cheap and is trading at an attractive valuation should take a closer look at Confluent, as it seems capable of stepping on the gas in the long run. Should you invest $1,000 in Confluent right now? Before you buy stock in Confluent, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Confluent wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $653,427!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,119,863!* Now, it's worth noting Stock Advisor's total average return is 1,060% — a market-crushing outperformance compared to 182% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 4, 2025
